Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease : A Population-Based Cohort Study.

ABSTRACT:

Background

Two recent randomized clinical trials of escalating doses of allopurinol for the progression of chronic kidney disease (CKD) reported no benefits but potentially increased risk for death. Whether the risk could occur in patients with gout and concurrent CKD remains unknown.

Objective

To examine the relation of allopurinol initiation, allopurinol dose escalation, and achieving target serum urate (SU) level after allopurinol initiation to all-cause mortality in patients with both gout and CKD.

Design

Cohort study.

Setting

The Health Improvement Network U.K. primary care database (2000 to 2019).

Participants

Patients aged 40 years or older who had gout and concurrent moderate-to-severe CKD.

Measurements

The association between allopurinol

SUBMITTER: Wei J 

PROVIDER: S-EPMC10445508 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature